BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Koskas M, Amant F, Mirza MR, Creutzberg CL. Cancer of the corpus uteri: 2021 update. Int J Gynaecol Obstet 2021;155 Suppl 1:45-60. [PMID: 34669196 DOI: 10.1002/ijgo.13866] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 19.0] [Reference Citation Analysis]
Number Citing Articles
1 deSouza NM, Choudhury A, Greaves M, O’connor JPB, Hoskin PJ. Imaging hypoxia in endometrial cancer: How and why should it be done? Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.1020907] [Reference Citation Analysis]
2 Wang P, Yang S, Liu C, Chang W, Lee F, Lee W. Endometrial cancer: Part I. Basic concept. Taiwanese Journal of Obstetrics and Gynecology 2022;61:951-959. [DOI: 10.1016/j.tjog.2022.09.001] [Reference Citation Analysis]
3 Li Y, Yang S, Wang P. Molecular pathology and prognosis of endometrial cancer. Taiwanese Journal of Obstetrics and Gynecology 2022;61:921-922. [DOI: 10.1016/j.tjog.2022.06.011] [Reference Citation Analysis]
4 Li Y, Yang S, Wang P. Cylindromatosis (CYLD) expression and prognosis of endometrial cancer. Taiwanese Journal of Obstetrics and Gynecology 2022;61:1093-1094. [DOI: 10.1016/j.tjog.2022.06.015] [Reference Citation Analysis]
5 Chiu WK, Kwok ST, Wang Y, Luk HM, Chan AHY, Tse KY. Applications and Safety of Sentinel Lymph Node Biopsy in Endometrial Cancer. JCM 2022;11:6462. [DOI: 10.3390/jcm11216462] [Reference Citation Analysis]
6 Liu Z, Yang H, Chen Z, Jing C. A novel chromatin regulator-related immune checkpoint related gene prognostic signature and potential candidate drugs for endometrial cancer patients. Hereditas 2022;159:40. [PMID: 36253800 DOI: 10.1186/s41065-022-00253-w] [Reference Citation Analysis]
7 Zvezdkina EA, Kedrova AG, Lebedev DP, Panchenkov DN, Stepanova YA. Specific characteristics of the magnetic resonance imaging for transarterial chemoembolization with drug-saturated microspheres in oncogynecology. Almanac of Clinical Medicine 2022. [DOI: 10.18786/2072-0505-2022-50-033] [Reference Citation Analysis]
8 Tian Y, Wen F, Wang S, Lv N. LHX1 as a potential biomarker regulates EMT induction and cellular behaviors in uterine corpus endometrial carcinoma. Clinics (Sao Paulo) 2022;77:100103. [PMID: 36116266 DOI: 10.1016/j.clinsp.2022.100103] [Reference Citation Analysis]
9 Zvezdkina EA, Kedrova AG, Lebedev DP, Greyan TA, Panchenkov DN, Stepanova YA. Transarterial chemoembolization in the treatment of primary and recurrent pelvic tumors with peritoneal involvement: what results can be expected? Opuholi ženskoj reproduktivnoj sistemy 2022;18:86-92. [DOI: 10.17650/1994-4098-2022-18-2-86-92] [Reference Citation Analysis]
10 Jiang D, Niu Z, Tan X, He H, Ren L, Shen J, Zhu X, Zhao P, Liu M, Chen H, Wang R, Li Q, Cao G. The mortalities of female-specific cancers in China and other countries with distinct socioeconomic statuses: A longitudinal study. J Adv Res 2022:S2090-1232(22)00204-1. [PMID: 36130684 DOI: 10.1016/j.jare.2022.09.002] [Reference Citation Analysis]
11 Yu Y, Zhang L, Sultana B, Wang B, Sun H. Diagnostic value of integrated 18F-FDG PET/MRI for staging of endometrial carcinoma: comparison with PET/CT. BMC Cancer 2022;22:947. [PMID: 36050751 DOI: 10.1186/s12885-022-10037-0] [Reference Citation Analysis]
12 Parpex G, Lieng C, Koskas M. Less is more in endometrial cancer (SLN, conservative treatment, radical hysterectomy, molecular classification). Curr Opin Oncol 2022;34:511-7. [PMID: 35943439 DOI: 10.1097/CCO.0000000000000874] [Reference Citation Analysis]
13 Maheshwari E, Nougaret S, Stein EB, Rauch GM, Hwang KP, Stafford RJ, Klopp AH, Soliman PT, Maturen KE, Rockall AG, Lee SI, Sadowski EA, Venkatesan AM. Update on MRI in Evaluation and Treatment of Endometrial Cancer. Radiographics 2022;:220070. [PMID: 36018785 DOI: 10.1148/rg.220070] [Reference Citation Analysis]
14 Shah VI, McCluggage WG. Clinical utility of pathology data: endometrial and tubo-ovarian carcinomas. J Clin Pathol 2022;75:529-36. [PMID: 35853653 DOI: 10.1136/jclinpath-2022-208207] [Reference Citation Analysis]
15 Wu S, Yu K, Lian Z, Deng S. Molecular Regulation of Androgen Receptors in Major Female Reproductive System Cancers. IJMS 2022;23:7556. [DOI: 10.3390/ijms23147556] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Hou X, Yue S, Liu J, Qiu Z, Xie L, Huang X, Li S, Hu L, Wu J. Association of Tumor Size With Prognosis in Patients With Resectable Endometrial Cancer: A SEER Database Analysis. Front Oncol 2022;12:887157. [DOI: 10.3389/fonc.2022.887157] [Reference Citation Analysis]
17 Feng Y, Wang Z, Xiao M, Li J, Su Y, Delvoux B, Zhang Z, Dekker A, Xanthoulea S, Zhang Z, Traverso A, Romano A, Zhang Z, Liu C, Gao H, Wang S, Qian L. An Applicable Machine Learning Model Based on Preoperative Examinations Predicts Histology, Stage, and Grade for Endometrial Cancer. Front Oncol 2022;12:904597. [PMID: 35712473 DOI: 10.3389/fonc.2022.904597] [Reference Citation Analysis]
18 Hoivik EA. Genomic Landscapes and Tumor Evolution in Metastatic Gynecological Cancers. Metastasis 2022. [DOI: 10.36255/exon-publications.metastasis.gynecological-cancers] [Reference Citation Analysis]
19 Tanaka C, Kobori T, Okada R, Doukuni R, Tameishi M, Urashima Y, Ito T, Takagaki N, Obata T. Ezrin Regulates the Cell Surface Localization of PD-L1 in HEC-151 Cells. JCM 2022;11:2226. [DOI: 10.3390/jcm11082226] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
20 Crosbie EJ, Kitson SJ, Mcalpine JN, Mukhopadhyay A, Powell ME, Singh N. Endometrial cancer. The Lancet 2022;399:1412-28. [DOI: 10.1016/s0140-6736(22)00323-3] [Cited by in Crossref: 22] [Cited by in F6Publishing: 14] [Article Influence: 22.0] [Reference Citation Analysis]
21 Liu Y, Wang H, Gao Y, Ahmad S. Controversy on Positive Peritoneal Cytology of Endometrial Carcinoma. Computational and Mathematical Methods in Medicine 2022;2022:1-5. [DOI: 10.1155/2022/1906769] [Reference Citation Analysis]
22 Zuna RE. Diagnostic Cytopathology of Peritoneal Washings. Cytojournal 2022;19:9. [DOI: 10.25259/cmas_02_07_2021] [Reference Citation Analysis]
23 Drocaş I, Crăiţoiu Ş, Stepan AE, Drocaş IA, Stepan MD. Clinicopathological Prognostic Parameters of Endometrioid Endometrial Carcinomas. Curr Health Sci J 2022;48:187-95. [PMID: 36320878 DOI: 10.12865/CHSJ.48.02.08] [Reference Citation Analysis]
24 Drocaş I, Crăiţoiu Ş, Stepan AE, Simionescu CE, Marinescu D. VEGF Immunoexpression in Endometrioid Endometrial Carcinomas. Curr Health Sci J 2022;48:155-61. [PMID: 36320870 DOI: 10.12865/CHSJ.48.02.03] [Reference Citation Analysis]
25 Singh N, Mishra N, Jayraj AS, Ghatage P. Management of Gynecologic Cancer During COVID-19 Pandemic: South Asian Perspective. Cancer Control 2022;29:10732748221119349. [PMID: 36036360 DOI: 10.1177/10732748221119349] [Reference Citation Analysis]
26 孙 方. Relation between the Levels of SII, FAR, CA125 and Clinicopathological Features of Endometrial Carcinoma. ACM 2021;11:5956-5963. [DOI: 10.12677/acm.2021.1112882] [Reference Citation Analysis]